



THE UNIVERSITY OF TEXAS

~~MD Anderson~~
Cancer Center

Making Cancer History®

The magnitude of dose calculation errors as a component of the IROC lung and spine phantom failures

Sharbacha S. Edward, Mallory C. Glenn, Christine B. Peterson, Peter A. Balter, Rebecca M. Howell, Julianne M. Pollard-Larkin, David S. Followill
Stephen F. Kry




IROC Houston Phantom Credentialing

- Clinical trial participation (Followill et al. 2012)
 - Irradiate phantoms that represent human anatomy
 - Over 2000 institutions in U.S. and abroad



Fig. 1 Thoracic phantom



IROC Houston Phantom Credentialing

- Deliver 6 Gy to TLD and film

Moving lung phantom

Criteria:

- TLD $\pm 7\%$, gamma 7% , 5 mm

Failure rate:

$$^{141}/_{1052} = 13\% \text{ (2012-2018)}$$

SBRT spine phantom

Criteria:

- TLD $\pm 7\%$, gamma 5% , 3 mm

Failure rate:

$$^{46}/_{263} = 17\% \text{ (2012-2018)}$$

Questions to answer:

- Are there dose calculation errors in these treatment plans?
- What is the magnitude of this error?
- How much does this error influence phantom failure?

Method

- 188 phantom plans: 60 spine, 128 lung
- Recalculated plan dose on independent dose recalculation system (DRS)
 - previously commissioned with data from over 500 LINACs (Kerns et al 2016)
 - represents average-performing machine (generic model)

- Compared for each phantom:
 - i. TPS/TLD
 - ii. DRS/TLD


- Dose difference value (D)

$$D = \left(\left| 1 - \frac{\text{TPS}}{\text{TLD}} \right| - \left| 1 - \frac{\text{DRS}}{\text{TLD}} \right| \right) \times 100$$

- D value = TPS more accurate

+ D value = DRS more accurate


Spine results: Number of phantoms



DRS outperformed TPS in:

- 52% of total phantoms
- 38% of passing phantoms
- **93% of failing phantoms**


Spine results: Magnitude of Dose difference



Average magnitude of D for failing spine phantoms = 2.11% (max = 5.25%)

D > 2% indicates DRS clinically considerably better than TPS calculation (Kerns et al 2017)


Lung results: Number of phantoms



DRS outperformed TPS in:

- 31% of total phantoms
- 32% of passing phantoms
- 28% of failing phantoms

Lung results: Magnitude of Dose difference



Negative D values in all categories indicating few dose calculation errors.

Lung vs Spine Performance

- Spine- highly modulated treatment plan
 - Tumor located on vertebral column near spinal cord
- Lung- low modulation treatment plan
 - Tumor located in air cavity

DRS vs TPS Performance

- DRS represents average-performing machines (average TrueBeam, average Versa etc.)
- DRS should not outperform TPS which is custom-tailored to an institution's machine and beam model

Conclusion

Spine:

- TPS and DRS performed fairly evenly overall (48% vs 52%)
- DRS remarkably better among failing phantoms (93%)

Dose calculation errors do exist among failing spine phantoms

Conclusion

Lung:

- TPS outperformed DRS in all phantom categories

Few dose calculation errors exist among lung phantoms

Future Work

- Investigate dose calculation errors in other phantom groups
- Evaluate other potential sources of error among phantoms

Acknowledgements:

- Lab mate:
Mallory C. Glenn
- IROC Houston staff & physicists
- Advisory Committee:
Peter A. Balter, PhD
Julianne M. Pollard-Larkin, PhD
Christine B. Peterson, PhD
Rebecca M. Howell, PhD
- PhD Advisor:
Stephen F. Kry, PhD

Work funded by
the NCI



Sharbacha Edward
Contact: sedward@mdanderson.org